ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2024
Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Adipose Tissue Expandability as a Link Between Nutrition and Obesity-Related Metabolic Risk: Insights from Bariatric Surgery.Nutrients · 2026Review
- Intrapancreatic fat deposition shows distinct regional and compartmental associations with obesity and diabetes.iScience · 2026Article
- Metabolically healthy obesity is independently associated with 20-year incidence of cardiovascular disease: findings from the ATTICA cohort study (2002-2022).International journal of obesity (2005) · 2026Article
- Pancreatic Steatosis as a Risk Phenotype for Pancreatic Ductal Adenocarcinoma: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Non-Pharmaceutical Interventions Based on Diet Restriction and Exercise Improve Morphology and Function of Fatty Pancreas in MaleInternational journal of molecular sciences · 2026Article
- A case report of young-onset type 2 diabetes patient with severe metabolic dysregulation carrying anFrontiers in endocrinology · 2026Article
- Non-alcoholic fatty pancreas disease (NAFPD) as a pre-neoplastic niche: Metabolic and inflammatory Gateways to pancreatic ductal adenocarcinoma.Journal of clinical & translational endocrinology · 2025Review
- Significance of Pancreatic Steatosis as a Predictor of New-Onset Diabetes Mellitus Following Pancreatectomy.Pancreas · 2025Article
- Fatty pancreas disease in newly diagnosed type 2 diabetes patients: a case-control study on relationships with glycemic control and exocrine function.Diabetology & metabolic syndrome · 2025Article
- Western diet-induced ultrastructural changes in mouse pancreatic acinar cells.Frontiers in cell and developmental biology · 2024Article
- NAFPD exacerbation by hyperlipidemia combined with hyperuricemia: a pilot rat experiment in lipidomics.Frontiers in nutrition · 2024Article
- Exploring the heterogeneity of hepatic and pancreatic fat deposition in obesity: implications for metabolic health.Frontiers in endocrinology · 2024Observational
- Prevalence of fatty pancreas and its relation with anthropometric values on the Growth and Obesity Cohort Study.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Alcoholic Fatty Pancreas disease (NAFPD), characterized by fat accumulation in pancreatic tissue, is an emerging clinical entity. However, the clinical associations, the underlying molecular drivers, and the pathophysiological mechanisms of NAFPD have not yet been characterized in detail. The NAFPD spectrum not only includes infiltration and accumulation of fat within and between pancreatic cells but also involves several inflammatory processes, dysregulation of physiological metabolic pathways, and hormonal defects. A deeper understanding of the underlying molecular mechanisms is key to correlate NAFPD with clinical entities including non-alcoholic fatty liver disease, metabolic syndrome, diabetes mellitus, atherosclerosis, as well as pancreatic cancer and pancreatitis. The aim of this review is to examine the pathophysiological mechanisms of NAFPD and to assess the possible causative/predictive risk factors of NAFPD-related clinical syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.